Monopar Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32%.

Top 23 shareholders own 53.91% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
42%	Tactic Pharma LLC	7,333,334	US$4.8m	0%	no data
3.97%	Jeffrey Klunzinger	692,800	US$450.3k	0%	no data
2.69%	Diane Hendricks	468,750	US$304.7k	0%	no data
1.35%	Michael Brown	235,863	US$153.3k	0%	no data
0.95%	Chandler Robinson	166,131	US$108.0k	29.4%	no data
0.43%	Christopher Starr	75,263	US$48.9k	0%	no data
0.33%	Andrew Cittadine	57,624	US$37.5k	11.3%	no data
0.29%	Kim Tsuchimoto	50,470	US$32.8k	32.9%	no data
0.28%	Renaissance Technologies LLC	48,086	US$31.3k	0%	no data
0.26%	The Vanguard Group, Inc.	45,167	US$29.4k	-48.4%	no data
0.24%	Geode Capital Management, LLC	41,199	US$26.8k	0%	no data
0.18%	Arthur Klausner	30,863	US$20.1k	0%	no data
0.17%	Millennium Management LLC	29,341	US$19.1k	54.4%	no data
0.16%	Gerber, LLC	28,005	US$18.2k	0%	0.02%
0.16%	Virtu Financial LLC, Asset Management Arm	27,170	US$17.7k	0%	no data
0.15%	Raymond Anderson	26,863	US$17.5k	0%	no data
0.082%	Two Sigma Investments, LP	14,302	US$9.3k	0%	no data
0.068%	UBS Asset Management AG	11,899	US$7.7k	16,400%	no data
0.063%	Susquehanna International Group, LLP, Asset Management Arm	10,993	US$7.1k	5.09%	no data
0.061%	Rappaport Reiches Capital Management, LLC	10,695	US$7.0k	0%	no data
0.021%	Tower Research Capital LLC	3,618	US$2.4k	-2.92%	no data
0.0046%	Morgan Stanley, Investment Banking and Brokerage Investments	800	US$519.6	0%	no data
0.00021%	Wells Fargo & Company, Private Banking and Investment Banking Arm	37	US$23.8	12.1%	no data